Invesaro

Stocks CMMB Earnings

Earnings

Chemomab Therapeutics Ltd. (CMMB) earnings

Quarterly results of Chemomab Therapeutics Ltd. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when CMMB files with the SEC.

Latest quarter: Q1 FY2023

In Q1 FY2023 (ended March 31, 2023) Chemomab Therapeutics Ltd. reported revenue of - and a net loss of $8.8M.

Diluted earnings per share were $0.04 (+81.8% on the same quarter a year earlier).

Net income by quarter
Q2 21: -$2.8M -$2.8M Q2 21Q3 21: -$3M -$3M Q3 21Q4 21: -$5M -$5M Q4 21Q1 22: -$5.1M -$5.1M Q1 22Q2 22: -$6.2M -$6.2M Q2 22Q3 22: -$8.1M -$8.1M Q3 22Q4 22: -$8.3M -$8.3M Q4 22Q1 23: -$8.8M -$8.8M Q1 23

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q1 FY2023March 31, 2023---$8.8M$0.04
Q4 FY2022December 31, 2022---$8.3M-
Q3 FY2022September 30, 2022---$8.1M$0.04
Q2 FY2022June 30, 2022---$6.2M$0.03
Q1 FY2022March 31, 2022---$5.1M$0.02
Q4 FY2021December 31, 2021---$5M-
Q3 FY2021September 30, 2021---$3M$0.01
Q2 FY2021June 30, 2021---$2.8M$0.01

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Get an email when CMMB reports

Follow CMMB and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when CMMB files with the SEC.

Source: quarterly figures Chemomab Therapeutics Ltd. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Chemomab Therapeutics Ltd.